Walking Speed is the Sole Determinant of Mild Cognitive Impairment in Japanese Patients with type 2 Diabetes Mellitus

Diabetes is a risk factor for mild cognitive impairment (MCI) and dementia. However, how the clinical characteristics of type 2 diabetic patients with MCI are linked to sarcopenia and/or its criterion remain to be elucidated. Japanese patients with type 2 diabetes mellitus were categorized into the MCI group for MoCA-J (the Japanese version of the Montreal cognitive assessment) score <26, and into the non-MCI group for MoCA-J ≥26. Sarcopenia was defined by a low skeletal mass index along with low muscle strength (handgrip strength) or low physical performance (walking speed <1.0 m/s). Univariate and multivariate-adjusted odds ratio models were used to determine the independent contributors for MoCA-J <26. Among 438 participants, 221 (50.5%) and 217 (49.5%) comprised the non-MCI and MCI groups, respectively. In the MCI group, age (61 ± 12 vs. 71 ± 10 years, p < 0.01) and duration of diabetes (14 ± 9 vs. 17 ± 9 years, p < 0.01) were higher than those in the non-MCI group. Patients in the MCI group exhibited lower hand grip strength, walking speed, and skeletal mass index, but higher prevalence of sarcopenia. Only walking speed (rather than muscle loss or muscle weakness) was found to be an independent determinant of MCI after adjusting for multiple factors, such as age, gender, BMI, duration of diabetes, hypertension, dyslipidemia, smoking, drinking, eGFR, HbA1c, and history of coronary heart diseases and stroke. In subgroup analysis, a group consisting of male patients aged ≥65 years, with BMI <25, showed a significant OR for walking speed. This is the first study to show that slow walking speed is a sole determinant for the presence of MCI in patients with type 2 diabetes. It was suggested that walking speed is an important factor in the prediction and prevention of MCI development in patients with diabetes mellitus.

Download Full-text

Walking Speed is the Sole Determinant Criterion of Sarcopenia of Mild Cognitive Impairment in Japanese Elderly Patients with Type 2 Diabetes Mellitus

Journal of Clinical Medicine ◽

10.3390/jcm9072133 ◽

2020 ◽

Vol 9 (7) ◽

pp. 2133

Author(s):

Noritaka Machii ◽

Akihiro Kudo ◽

Haruka Saito ◽

Hayato Tanabe ◽

Mariko Iwasaki ◽

...

Keyword(s):

Diabetes Mellitus ◽

Type 2 Diabetes ◽

Type 2 Diabetes Mellitus ◽

Cognitive Impairment ◽

Mild Cognitive Impairment ◽

Walking Speed ◽

Duration Of Diabetes ◽

Skeletal Mass ◽

Prediction And Prevention

Diabetes mellitus is a risk factor for mild cognitive impairment (MCI) and dementia. However, how the clinical characteristics of MCI patients with type 2 diabetes mellitus are linked to sarcopenia and/or its criteria remain to be elucidated. Japanese patients with type 2 diabetes mellitus were categorized into the MCI group for MoCA-J (the Japanese version of the Montreal cognitive assessment) score <26, and into the non-MCI group for MoCA-J ≥26. Sarcopenia was defined by a low skeletal mass index along with low muscle strength (handgrip strength) or low physical performance (walking speed <1.0 m/s). Univariate and multivariate-adjusted odds ratio models were used to determine the independent contributors for MoCA-J <26. Among 438 participants, 221 (50.5%) and 217 (49.5%) comprised the non-MCI and MCI groups, respectively. In the MCI group, age (61 ± 12 vs. 71 ± 10 years, p < 0.01) and duration of diabetes mellitus (14 ± 9 vs. 17 ± 9 years, p < 0.01) were higher than those in the non-MCI group. Patients in the MCI group exhibited lower hand grip strength, walking speed, and skeletal mass index, but higher prevalence of sarcopenia. Only walking speed (rather than muscle loss or muscle weakness) was found to be an independent determinant of MCI after adjusting for multiple factors, such as age, gender, body mass index (BMI), duration of diabetes mellitus, hypertension, dyslipidemia, smoking, drinking, estimated glomerular filtration rate (eGFR), HbA1c, and history of coronary heart diseases and stroke. In subgroup analysis, a group consisting of male patients aged ≥65 years, with BMI <25, showed a significant OR for walking speed. This study showed that slow walking speed is a sole determinant criterion of sarcopenia of MCI in patients with type 2 diabetes mellitus. It was suggested that walking speed is an important factor in the prediction and prevention of MCI development in patients with diabetes mellitus.

Download Full-text

Walking Speed is the Sole Determinant of mild Cognitive Impairment in Japanese Patients with Type 2 Diabetes Mellitus

10.21203/rs.3.rs-20599/v1 ◽

2020 ◽

Author(s):

Noritaka Machii ◽

Akihiro Kudo ◽

Haruka Saito ◽

Hayato Tanabe ◽

Mariko Iwasaki ◽

...

Keyword(s):

Diabetes Mellitus ◽

Type 2 Diabetes ◽

Type 2 Diabetes Mellitus ◽

Cognitive Impairment ◽

Mild Cognitive Impairment ◽

Walking Speed ◽

Duration Of Diabetes ◽

Skeletal Mass ◽

Prediction And Prevention

Abstract Background To elucidate the clinical characteristics of type 2 diabetes mellitus patients with mild cognitive impairment (MCI) and to examine whether diagnosis of sarcopenia and/or its criterion are explanatory factors for MCI Methods Patients with type 2 diabetes mellitus were categorized into the MCI group for MoCA-J (the Japanese version of the Montreal cognitive assessment) score <26, and into the non-MCI group for MoCA-J ≥26. Sarcopenia was defined by a low skeletal mass index along with low muscle strength (handgrip strength) or low physical performance (walking speed <1.0 m/s). Univariate and multivariate-adjusted odds ratio models were used to determine the independent contributors for MoCA-J <26. Results Among 438 participants, 221 (50.5%) and 217 (49.5%) comprised the non-MCI and MCI groups, respectively. In the MCI group, age (61 ± 12 vs. 71 ± 10 years, p < 0.01) and duration of diabetes (14 ± 9 vs. 17 ± 9 years, p < 0.01) were higher than those in the non-MCI group. Patients in the MCI group exhibited lower hand grip strength, walking speed, and skeletal mass index, but higher prevalence of sarcopenia. Only walking speed (rather than muscle loss or muscle weakness) was found to be an independent determinant of MCI after adjusting for multiple factors, such as age, gender, BMI, duration of diabetes, hypertension, dyslipidemia, smoking, drinking, eGFR, HbA1c, and history of coronary heart diseases and stroke. In subgroup analysis, a group consisting of male patients aged ≥65 years, with BMI <25, showed a significant OR for walking speed. Conclusions This is the first study to show that slow walking speed is a determinant for the presence of MCI in patients with type 2 diabetes. It was suggested that walking speed is an important factor in the prediction and prevention of MCI development in patients with diabetes mellitus.

Download Full-text

Association of serum cystatin C and risk of mild cognitive impairment in elderly patients with type 2 diabetes mellitus

Academic Journal of Second Military Medical University ◽

10.3724/sp.j.1008.2011.01122 ◽

2011 ◽

Vol 31 (10) ◽

pp. 1122-1125

Author(s):

Lan LUO ◽

Yu-hong HU ◽

Xi-ping TUO

Keyword(s):

Diabetes Mellitus ◽

Type 2 Diabetes ◽

Type 2 Diabetes Mellitus ◽

Cognitive Impairment ◽

Mild Cognitive Impairment ◽

Elderly Patients ◽

Cystatin C ◽

Serum Cystatin C ◽

Serum Cystatin

Download Full-text

Risk factors for developing dementia in type 2 diabetes mellitus patients with mild cognitive impairment

Neuropsychiatric Disease and Treatment ◽

10.2147/ndt.s189905 ◽

2019 ◽

Vol Volume 15 ◽

pp. 167-175 ◽

Cited By ~ 16

Author(s):

Oana Albai ◽

Mirela Frandes ◽

Romulus Timar ◽

Deiana Roman ◽

Bogdan Timar

Keyword(s):

Diabetes Mellitus ◽

Risk Factors ◽

Type 2 Diabetes ◽

Type 2 Diabetes Mellitus ◽

Cognitive Impairment ◽

Mild Cognitive Impairment

Download Full-text

Feature Classification Method of Resting-State EEG Signals From Amnestic Mild Cognitive Impairment With Type 2 Diabetes Mellitus Based on Multi-View Convolutional Neural Network

IEEE Transactions on Neural Systems and Rehabilitation Engineering ◽

10.1109/tnsre.2020.3004462 ◽

2020 ◽

Vol 28 (8) ◽

pp. 1702-1709 ◽

Cited By ~ 1

Author(s):

Dong Wen ◽

Peng Li ◽

Yanhong Zhou ◽

Yanbo Sun ◽

Jian Xu ◽

...

Keyword(s):

Neural Network ◽

Diabetes Mellitus ◽

Type 2 Diabetes ◽

Type 2 Diabetes Mellitus ◽

Cognitive Impairment ◽

Mild Cognitive Impairment ◽

Resting State ◽

Amnestic Mild Cognitive Impairment ◽

Eeg Signals

Download Full-text

Association between plasma adipsin level and mild cognitive impairment in Chinese patients with type 2 diabetes: a cross-sectional study

BMC Endocrine Disorders ◽

10.1186/s12902-019-0431-y ◽

2019 ◽

Vol 19 (1) ◽

Cited By ~ 1

Author(s):

Dan Guo ◽

Yang Yuan ◽

Rong Huang ◽

Sai Tian ◽

Jiaqi Wang ◽

...

Keyword(s):

Diabetes Mellitus ◽

Insulin Resistance ◽

Type 2 Diabetes ◽

Type 2 Diabetes Mellitus ◽

Cognitive Impairment ◽

Mild Cognitive Impairment ◽

Large Scale ◽

Chinese Patients ◽

Enzyme Linked Immunosorbent Assay

Abstract Background The adipokine adipsin contributes to insulin resistance (IR), inflammation, and obesity, which are all regarded as high-risk factors for mild cognitive impairment (MCI) in patients with type 2 diabetes mellitus. This research aimed to uncover the role of adipsin in Chinese type 2 diabetes mellitus (T2DM) population with early cognitive dysfunction and determine whether adipsin contributes to diabetic MCI caused by IR. Methods In our study, 126 patients with T2DM were enrolled. The Montreal Cognitive Assessment (MoCA) was used to assess cognitive impairment. Demographic data and neuropsychological test results were evaluated. Plasma adipsin level was measured by enzyme-linked immunosorbent assay. Results The MCI group (n = 57) presented higher plasma adipsin levels compared with the healthy controls (p = 0.018). After adjustment for educational attainment, and age, begative correlations were found between plasma adipsin levels and MoCA, Mini Mental State Exam, and Verbal Fluency Test scores(r = − 0.640, p < 0.001; r = − 0.612, p < 0.001; r = − 0.288, p = 0.035; respectively). Correlation analysis demonstrated that adipsin levels were significantly positively correlated with fasting C-peptide; homeostasis model of assessment for insulin resistance (HOMA-IR) (r = 0.368, p < 0.001; r = 0.494, p < 0.001; respectively). Multivariable regression analysis further indicated that high plasma adipsin level was a significant independent determinant of MCI in the Chinese population withT2DM (p = 0.017). Conclusions Elevated plasma adipsin level was associated with MCI in Chinese T2DM patients. Further large-scale studies should be designed to determine whether adipsin is linked to IR-associated susceptibility to early cognitive decline in T2DM patients.

Download Full-text